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Abstract 
Visceral myopathy with abnormal intestinal and bladder peristalsis includes a clinical 
spectrum with Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS), 
and Chronic Intestinal Pseudo-Obstruction (CIPO). The vast majority of cases are caused 
by dominant variants in ACTG2; however, the overall genetic architecture of visceral 
myopathy has not been well-characterized. We ascertained 53 families, with visceral 
myopathy based on megacystis, functional bladder/gastrointestinal obstruction or 
microcolon. A combination of targeted ACTG2 sequencing and exome sequencing was 
used. We report a molecular diagnostic rate of 64% (34/53), of which 97% (33/34) is 
attributed to ACTG2. Strikingly, missense mutations in five conserved arginine residues 
involving CpG dinucleotides, accounted for 49% (26/53) of disease in the cohort. As a 
group, the ACTG2- negative cases had a more favorable clinical outcome and more 
restricted disease. Within the ACTG2-positive group, poor outcomes (characterized by 
total parenteral nutrition dependence, death or transplantation) were invariably due to one 
of the arginine missense alleles. Analysis of specific residues suggests a severity 
spectrum of p.Arg178 > p.Arg257 > p.Arg40 along with other less frequently reported 
sites p.Arg63 and p.Arg211. These results provide genotype-phenotype correlation for 












ACTG2-related disease and demonstrate the importance of arginine missense changes in 
visceral myopathy.  
KeyWords: Megacystis-Microcolon Intestinal Hypoperistalsis, ACTG2, visceral 
myopathy, dysmotility, smooth muscle 
Introduction 
Visceral myopathy (MIM# 155310) is a rare disorder of smooth muscle dysfunction with 
phenotypes ranging from massively distended bladder requiring catheterization with 
functional intestinal dysmotility causing severe feeding intolerance to a milder 
presentation with a predominant involvement of the gastrointestinal system manifesting 
as intermittent abdominal distention and functional intestinal obstruction. Clinicians have 
characterized patients within this broad phenotypic spectrum as Megacystis Microcolon 
Intestinal Hypoperistalsis Syndrome (MMIHS), Chronic Intestinal Pseudo-Obstruction 
(CIPO), or hollow visceral myopathy. The rarity of the disease and the overlap between 
the different phenotypes have made it difficult to accurately determine the incidence and 
prevalence (Downes, Cheruvu, Karunaratne, De Giorgio, & Farmer, 2018). A nationwide 
epidemiologic survey in Japan reported CIPO prevalence of 1.0 and 0.8 cases per 
100,000 in males and females, respectively, with an incidence of 0.21 and 0.24 cases per 
100,000 (Iida, Ohkubo, Inamori, Nakajima, & Sato, 2013). In the United States, it has 
previously been estimated that approximately 100 infants with CIPO are born every year 
(Di Lorenzo, 1999). 
A number of genes have been identified underlying these phenotypes with the majority of 
molecularly diagnosed cases caused by monoallelic variants in ACTG2 resulting in 












dominant alleles, with biallelic variants in additional smooth muscle genes underlying 
some recessive cases. 
The genetic basis of visceral myopathy remained elusive for many years. While some 
studies implicated myopathy in MMIHS/CIPO (Puri, Lake, Gorman, O'Donnell, & 
Nixon, 1983; Rolle, O'Briain, Pearl, & Puri, 2002), others suggested abnormal 
innervation (Kapur, 2003), gastrointestinal hormonal imbalance (Hammar et al., 2012; 
Taguchi et al., 1989) and perturbation of the cells of Cajal, the intrinsic intestinal 
pacemaker (Piotrowska et al., 2003) as the underlying mechanism. Evidence from mouse 
models indicated that impairment of cholinergic neurotransmission, which initiates the 
process leading to smooth muscle contraction, results in dilated bladder, and mydriasis 
(Lev-Lehman, Bercovich, Xu, Stockton, & Beaudet, 2001).  
We and others identified ACTG2 as the first single gene for the disease traits of visceral 
myopathy (Lehtonen et al., 2012), and MMIHS/CIPO (Thorson et al., 2014; Wangler et 
al., 2014). Subsequent reports, supported by functional data from mouse models, 
established the important role of ACTG2 in these disorders (Halim et al., 2016; Holla, 
Bock, Busk, & Isfoss, 2014; Klar et al., 2015; Lu et al., 2016; Matera et al., 2016; 
Milunsky, Baldwin, et al., 2017; Milunsky, Lazier, et al., 2017; Moreno et al., 2016; 
Tuzovic et al., 2015; Whittington, Poole, Dutta, & Munn, 2017). ACTG2 encodes a 
muscle actin isoform predominantly expressed in the intestinal smooth muscle (Miwa et 
al., 1991; Szucsik & Lessard, 1995) which, together with myosin, comprises the 
apparatus responsible for muscle contraction and relaxation. 












While ACTG2 emerged as the first major causative gene, additional genes have been 
found to play a role in the pathogenesis. ACTA2 also encodes a smooth muscle actin 
gene; variation in it causes Multisystemic Smooth Muscle Dysfunction syndrome (MIM 
#613834). This Mendelian condition includes bladder hypotonicity and abnormal 
intestinal peristalsis; however, in those cases there is also significant involvement of 
vascular and ciliary smooth muscle leading to vascular aneurysms and mydriasis.  
Autosomal recessive forms of MMIHS are caused by biallelic loss-of-function variants in 
other proteins involved in actin-myosin interactions: MYH11 (myosin heavy chain) 
(Gauthier et al., 2015), MYLK (myosin light chain kinase) (Halim, Brosens, et al., 2017), 
LMOD1 (leiomodin 1, an actin-binding protein expressed primarily in vascular and 
visceral smooth muscle) (Halim, Wilson, et al., 2017) and MYL9 (regulatory myosin light 
chain) (Moreno et al., 2018). Other genes that are implicated in intestinal hypoperistalsis, 
but usually with other distinguishing phenotypic features include: genes causing 
mitochondrial disorders (TYMP, POLG); EDNRB, EDN3 and SOX10 associated with 
Waardenburg syndrome with Hirschprung disease; SGOL1; RAD21; FLNA and L1CAM.  
These studies have highlighted smooth muscle structural proteins and pathways related to 
smooth muscle function and provided mechanistic insight from case series and reports. 
Such novel gene discoveries provide further molecular insights into disease pathology, 
nevertheless heterozygous variants in ACTG2 remains the most common finding on 
molecular testing (Ravenscroft et al., 2018). Based on data from a small number of cases, 
some genotype-phenotype correlations have been proposed. In one series, three patients 
with missense mutations affecting Arg178 were found to have microcolon, while seven 
patients with Arginine substitutions at another site (Arg38, Arg148, Arg178) were not 












(Matera et al., 2016). In another cohort of 11 subjects, the observation of severe 
phenotypes was made for individuals with mutations affecting Arg178 (Halim et al., 
2016). However, these observations were not tested statistically due to the small number 
of cases. In addition, the overall likelihood of finding specific molecular diagnoses for 
these disorders has not been well defined as most reported cases come from a subset of 
molecularly diagnosed cases. We therefore studied 53 unrelated families with visceral 
myopathy and report an allelic series. The clinical findings, molecular diagnostic rates, 
and genotype-phenotype correlations in this cohort provide new insights into the genetic 
architecture of visceral myopathy.  
METHODS 
All patients were recruited to Baylor College of Medicine (BCM) Visceral Myopathy 
Cohort. All subjects provided informed consent for the study under IRB protocol (H-
29697) at Baylor College of Medicine. Patients were recruited to the study during two 
different time intervals; the first from 1999-2001, and then from 2013 to the present. 
Patients with clinical findings of prenatal or post-natal megacystis, microcolon, intestinal 
hypomotility across a range of ages, intestinal pseudo-obstruction, prune belly syndrome 
or dependence on total parenteral nutrition (TPN) due to intestinal functional obstruction 
were ascertained and referred or recruited. Subjects were excluded if they had 
documented spina bifida, diagnosed Hirschprung’s disease or known secondary cause for 
neurogenic bladder. We have previously described 15 probands from this cohort in the 
process of uncovering ACTG2 as the causative gene (Wangler et al., 2014). In another 
family in the cohort, homozygous variants in MYLK were later identified (Halim, 












Brosens, et al., 2017). DNA samples from these and additional probands and family 
members were isolated and stored for further studies. 
Targeted ACTG2 Sequencing 
We designed a set of primers that cover all the exons and intron-exon boundaries of the 
ACTG2 gene (Supp. Table S1). We utilized these for Targeted ACTG2 Sanger 
sequencing and for confirmation of results of research exome or external clinical exome 
and segregation studies in available family members.  
Exome Sequencing 
Genomic DNA (1 µg) was fragmented by sonication. Illumina paired-end libraries from 
genomic DNA samples were constructed (Lupski et al., 2013). Pre-capture libraries were 
pooled and hybridized in solution to the BCM-HGSC CORE exome capture design 
(Bainbridge et al., 2011) (52Mb, NimbleGen). Captured DNA fragments were sequenced 
on an Illumina HiSeq 2000 platform, producing 9-10 gigabase-pairs (Gb) of sequence for 
each personal genome and achieving an average of 95% of the targeted exome bases 
covered to an average depth of 20X or greater, with mean coverage of target bases of 
over 100X. Raw sequence reads were mapped and aligned to the GRCh37 (hg19) human 
genome reference assembly using the HGSC Mercury analysis pipeline 
(http://www.tinyurl.com/HGSC-Mercury/) (Reid et al., 2014) or the Baylor Genetics 
analysis pipeline (Liu et al., 2019).  
 
 












Clinical Data Analysis 
Study subjects recruited after 2013 were assessed by clinician or genetic counselor co-
authors by direct history, physical exam and pedigree analysis. In some cases, subjects 
had been previously referred from centers around the world prior to 2013 in which case 
medical information was gathered from communication with health care providers or 
review of medical records after authorization for release of medical information was 
provided by the families. In addition, we asked families direct questions to verify 
information, and determine physicians and hospitals for specific health history events. 
We also utilized a clinical questionnaire completed by the patients or their families to 
collect a standard set of data including demographic information and clinical symptoms. 
This was not possible for all the subjects such that 40 of 53 cases have complete clinical 
information.  
Meta-Analysis 
We performed a review of the literature for cohorts and case reports of ACTG2-related 
visceral myopathy/MMIHS/CIPO. For each of the unrelated probands we documented 
the ACTG2 variant, presence or absence of megacystis, microcolon, any gastrointestinal 
involvement, any genitourinary involvement and the outcome. Outcomes were arbitrarily 
divided into poor (defined as dependence on total parenteral nutrition, visceral transplant 
or death in early childhood) vs. more favorable outcome (all other cases). 
  













Clinical Characteristics of the BCM Visceral Myopathy Cohort  
The BCM cohort includes 53 probands with detailed clinical assessment available for 40 
cases and their families. The study population consisted of 66% female and 34% male 
probands consistent with previous studies suggesting a female preponderance (Table 1, 
Supp. Table S2) (Gosemann & Puri, 2011). Mean maternal age in the cohort was 31 
years (range 22-40) and mean paternal age was 32 years (range 20-44). 
We observed prenatal or postnatal megacystis in 77.8% with bladder catheterization 
requirement in 79.4% of our cohort, and a fetal bladder diversion surgery having been 
undertaken during pregnancy in four subjects (11.4%), two of whom were recruited in the 
first interval of ascertainment and two in the more recent recruitment (Table 1, Supp. 
Figure S1A-C). Microcolon was identified in 53% of the subjects and 52.8% of the 
subjects underwent abdominal surgery in the first weeks of life with bilious emesis noted 
in the first days of life in 43.7% (Table 1, Supp. Figure S1D-F). The overwhelming 
majority of the cohort required TPN or partial parenteral nutrition at some point in life, 
we noted that 30% of the subjects were totally dependent on TPN for nutrition, while an 
additional 47.2% required partial or temporary parenteral nutrition (Table 1, Supp. 
Figure S1G). Taken together, the subjects in our cohort represented a medically complex 
population of individuals with high rates of surgical, bladder and nutritional intervention 
with similar rates as previous clinical meta-analyses of MMIHS (Gosemann & Puri, 
2011).  












As a group, patients in the cohort had symptoms affecting both gastrointestinal (GI) and 
genitourinary (GU) systems such as megacystis and TPN dependence; however, there 
were five notable subjects (13.1%) with disease involvement apparently restricted to 
either the GI or the GU system (Supp. Figure S1H).  
We categorized a number of outcomes given the high rates of complications or medical 
procedures in the cohort. Subjects received care in different hospitals in different 
countries where medical practices could vary making surgical outcomes challenging to 
characterize. Patients with visceral myopathy can also have a number of complications 
related to previous abdominal surgery, infection of central lines, liver disease from long-
term TPN and hospital-related infections. We arbitrarily divided the cohort into 
dichotomous clinical groups defined on the basis of “poor outcomes” versus more 
“favorable outcomes” (Supp. Figure S1I).  
Molecular Diagnostic Rates 
The inheritances pattern of MMIHS varies depending on genetic cause with ACTG2 cases 
presenting as sporadic or a dominant trait (Wangler et al., 2014), but familial cases with 
consanguinity point to the recessive loci (Nakamura, O'Donnell, & Puri, 2019). In the 
present cohort, five families exhibited an apparently recessive pattern of inheritance 
where affected siblings had apparently unaffected parents (Fam10, Fam19, Fam33, 
Fam36, Fam44); consanguinity was reported in three of these cases (3/53, 5.6%). In four 
families the pedigree suggested a dominantly-inherited disease (affected child with 
affected parent; Fam13, Fam34, Fam53, Fam54). In the majority of cases (38/53, 71.7%) 
the disease was apparently sporadic (Figure 1A, Supp. Table S2).  












Upon molecular analysis, individuals in our cohort received a molecular diagnosis of a 
pathogenic mutation in 64.1% (34/53) of cases (Figure 1B, Table 1). Novel variants 
have been submitted to ClinVar. Overall, 20 subjects were diagnosed by targeted research 
testing of ACTG2 using Sanger sequencing or targeted next-generation sequencing, and 
another 14 subjects were found to have ACTG2 variants by exome sequencing for a total 
of 33 ACTG2 positive cases (Figure 1C). In one family with apparent recessive disease 
we previously identified a pathogenic homozygous MYLK variant (Halim et al., 2016) 
Of the cases that received a molecular diagnosis, 20 were due to de novo ACTG2 
variants, consistent with the observation of the cohort that the majority of the cases 
appear sporadically, and suggesting an estimate of 37.7% (20/53) of cases of visceral 
myopathy are due to de novo ACTG2 events (Figure 1D). We noted that 26/53 (49%) of 
the cases, both de novo and inherited had ACTG2 arginine missense substitutions (Figure 
1E). For 19 families a molecular pathogenic diagnosis has not been identified to date, 
including 17 sporadic cases and two pairs of siblings. Seven of these families had 
undergone trio exome sequencing.  
Clinical Features of the ACTG2 Positive Versus Negative Cases 
In comparing the cases in our cohort testing positive for an ACTG2 pathogenic variant to 
those without we noted clinical differences. Of the 28 individuals in our cohort with 
confirmed megacystis, 24 were ACTG2-positive (85.7%), while of the eight known to not 
have megacystis, only three of eight were positive for ACTG2 (37.5%) (Figure 2A). 
These results were statistically significant (Fisher’s Exact test, p=0.0132). Similarly, 
92.3% (24/26) of the ACTG2-positive cases required bladder catheterization, compared to 












only 37.5% (3/8) of the ACTG2 negative cases (Fisher’s Exact test, p=0.0035) (Figure 
2B). Microcolon was identified in 61.5% (16/26) of the ACTG2-positive cases, while 
only 25% (2/8) had microcolon in the ACTG2- negative cases (Figure 2C). Finally, 
abdominal surgery in the first weeks of life was performed in 57.7% (15/26) of the 
ACTG2-positive cases compared to 40% (4/10) in the ACTG2-negative cases (Figure 
2D). The differences in the frequencies of microcolon and abdominal surgery were not 
statistically significant (Fisher’s Exact test, p=0.11 and 0.4543, respectively). Taken 
together the ACTG2- positive and negative cases comprised somewhat clinically distinct 
groups, particularly in regard to the genitourinary features.  
We also noted that for each disease feature or complication classically defined in 
MMIHS (e.g. megacystis and microcolon), between 75-90% could be attributed to 
ACTG2 (Figure 3A). In addition, we noted that missense substitutions in arginine 
residues accounted for 49% of all the cases in our cohort (Figure 3B). Notably, there was 
a large difference in outcomes between the ACTG2-positive and ACTG2- negative groups 
(Figure 3C-D). Testing positive for ACTG2 in our cohort led to a 44.4% chance (12/27) 
of a patient having a poor outcome and severe disease, compared to a 16.7% chance 
(2/12) of a poor outcome in those testing negative, although these results were not 
statistically-significant (Fisher’s Exact test, p=0.1509). In aggregate, these data suggest 
stringent clinical selection of cases of severe visceral myopathy could predict high rates 
of positive ACTG2 testing (Figure 3C). Our findings demonstrate that the vast majority 
of cases with megacystis, microcolon, newborn abdominal surgery, bladder 
catheterization and poor long-term prognosis belong to an ACTG2-positive group. 












Overall, the undiagnosed group was more clinically heterogeneous than the ACTG2-
positive group. One case had prune belly syndrome with no GI involvement (Fam38-1). 
These cases also had a number of additional features reported including multiple 
congenital anomalies (Fam31-1), developmental delays and myoclonic jerks (Fam40-1), 
symptoms resembling postural orthostatic tachycardia syndrome (POTS) and recurrent 
pancreatitis (Fam45-1), spina bifida occulta (Fam48-1) and multiple café-au-lait macules 
in 2 siblings (Fam33-1, Fam33-4).  
Recurrent Arginine Missense Mutations in ACTG2 
The pathogenic variants in our cohort were all coding missense substitutions. These 
included 17 unique variants, affecting 12 unique amino acid positions of the ACTG2 
protein (Figure 4A, Supp. Table S3). The ACTG2 gene encodes a 376 amino acid actin 
protein which is nearly identical at the amino acid level to the five other paralogs in the 
human genome (ACTG1, ACTC1, ACTA1, ACTA2, ACTB) (Supp. Figure S2). All of the 
actin proteins share 18 identical arginine residues distributed across the protein. In 
ACTG2, 13 of the 18 arginine residues are encoded by a “CGX” (CGG, CGC, CGA, 
CGU) codon with a CpG dinucleotide at that site (Figure 4B, sites in red). We observed 
five recurrent arginine sites in which multiple recurrent arginine missense substitutions 
were identified (red stars). These sites accounted for 78.7% of the ACTG2 positive cases 
and nearly 50% of the cases in our entire cohort.  
Next, we examined public databases including gnomAD and ClinVar (Harrison et al., 
2016; Lek et al., 2016) and we catalogued which of these and the other arginine sites 
have been noted to have missense substitutions. We found that the five recurrent sites 












were all absent in gnomAD, but present in ClinVar. We also noted that p.Arg38 and 
p.Arg148 are additional arginine sites encoded by a CGX codon where subsitutions that 
are noted as pathogenic in ClinVar occur that are clearly causative for MMIHS from 
previous publications (Holla et al., 2014; Lehtonen et al., 2012; Matera et al., 2016; 
Ravenscroft et al., 2018), but interestingly missense variants at these two sites are also 
present in gnomAD (Figure 4C): p.Arg38Cys, p.Arg148Cys and p.Arg148His were each 
present in a heterozygous state with a minor allele frequency of 1/251154 (0.000004). Of 
note, we observed a total of ten stopgain ACTG2 alleles (six unique). Of these, four were 
an arginine nonsense mutation p.Arg211Ter with a minor allele frequency of 0.000017 in 
gnomAD. These findings of loss of function alleles in gnomAD but missing from clinical 
cohorts, are in line with our previous analysis that suggested that haploinsufficiency of 
ACTG2 is unlikely; indeed we had not observed these variants in our cohort (Wangler et 
al 2014).  
Our data pointed to a central and prevalent role for the ACTG2 locus in this disease 
phenotype, and to sporadic cases due to de novo events and less commonly dominant 
inherited disease. We examined the paternal ages in our cohort (Supp. Figure S3A) and 
observed a modest effect in which the average paternal age at time of birth in the families 
with a de novo ACTG2 mutation was 34 years versus 29 years in all other cases. This 
difference was statistically significant (Fisher’s Exact test, p=0.0432).  
Since the earliest efforts to apply genomics to MMIHS, consanguinity has been observed 
in some cases. Despite, the data on ACTG2 and de novo events, it was recently suggested 
that based on the rates of consanguinity that MMIHS should be considered primarily an 
autosomal recessive disorder (Nakamura et al., 2019). We therefore explored the apparent 












recessive cases in our cohort. Parental consanguinity was reported in three families in the 
cohort with affected siblings (Fam10, Fam33 and Fam36), of which one case was found 
to harbor a homozygous variant in MYLK (Fam36) (Halim, Brosens, et al., 2017). 
Interestingly, one other nonconsanguineous case that appeared recessive with two 
affected siblings, one of whom underwent intestinal transplant, was ultimately found to 
be due to the ACTG2 p.Arg178Cys variant (Supp. Figure S3B). Significant intra-familial 
variability was observed accounting for this observation as the siblings inherited a 
pathogenic variant in ACTG2 from their mother who had been undiagnosed. Notably, she 
had prolonged labor due to uterine atony, a feature also reported in another family 
(Fam51) in the cohort as well as other cases in the literature (Klar et al., 2015; Sipponen, 
Karikoski, Nuutinen, Markkola, & Kaitila, 2009). In an additional family with multiple 
affected members (Fam34) symptoms ranged from chronic constipation with or without 
urinary tract infections to severely affected individuals requiring catheterizations and 
abdominal surgeries (Supp. Figure S4A). Ages at diagnosis ranged from the prenatal 
period to adulthood in this family. Given the wide range of intrafamilial variability, 
apparent recessive cases with affected siblings still does not exclude a dominant model 
with incomplete penetrance in the parents, and ACTG2 testing can still be useful. We also 
postulated that parental mosaicism for ACTG2 could account for these observations but 
we did not observe mosaicism in our parental samples.  
We also had previously identified a variant in ACTG2 which appeared to affect an 
alternative transcript (NC_000002.11(NM_001615.3):c.255+210C>A encoding 
p.Phe110Leu on transcript Uc010fex.1). This variant was found in Fam19 in two affected 
siblings (Supp. Figure S4B). We then found this variant in another family Fam18, in 












which the proband and an unaffected sibling were positive for this variant. The Fam18-1 
proband was also positive for a de novo ACTG2 variant (NM_001615.3:c.770G>A; 
NM_001615.3:p.Arg257H). These data suggest the previously reported p.Phe110Leu 
allele may be a benign variant. However, an impact as a modifier or incompletely 
penetrant allele could not be ruled out (Supp. Figure S4B).  
Additional Clinical Features of ACTG2 Positive group 
The majority of individuals testing positive for ACTG2 exhibited the classic MMIHS 
phenotype including a combination of symptoms suggesting bladder and intestinal 
dysmotility. Two cases (Fam55-1, Fam57-1) presented initially with neurogenic bladder 
alone during the first months of life but later developed significant gastrointestinal 
dysmotility: Fam55-1 developed severe abdominal distension with Clostridium difficile 
infection at age 1 year and had an ileostomy performed. Fam57-1 presented with more 
severe bladder symptoms and no apparent GI dysmotility at birth, but by age four months 
she developed massive gastric distension requiring decompression by a gastric tube and 
was started on 80% parenteral nutrition. Prune belly was also seen in ACTG2 positive 
cases (Fam9, Fam16). In adult patients, features including cholecystitis, cholelithiasis, 
biliary sludge, gastric and colonic polyps, gastritis, hepatitis, nephrolithiasis and a simple 
renal cyst were reported. Developmental delays were noted in two cases: one subject with 
a p.Arg40His variant had mild initial gross motor delays (Fam49-1). Another subject with 
a p.Arg178Cys variant was born prematurely at 34 weeks. She had microcephaly, cortical 
thumbs, mild hypertonia and mild global developmental delays (Fam44-4). Chromosomal 
microarray analysis was nondiagnostic. Mydriasis was not noted in the ACTG2 positive 
subjects.  












ACTG2 Variants and Genotype-Phenotype Correlations 
Because we observed a high proportion of arginine missense substitutions in ACTG2 in 
our cohort, we sought to study whether these alleles were associated with differences in 
clinical outcomes. We reasoned that because these particular CGX codons were sites of 
recurrent mutation that predicting clinical outcomes from these alleles would be 
particularly useful as they are highly likely to continue to be observed in new cases. 
Indeed, it has previously been suggested that specific arginine missense variants such as 
those affecting the arginine residue at position 178 (Arg178) may have a higher rate of 
microcolon or early death (Halim et al., 2016; Matera et al., 2016). In our cohort, all the 
probands with variants affecting Arg178 were TPN-dependent, and at least one of them 
had undergone a multi-organ transplant including large and small intestine, spleen, 
pancreas, part of the esophagus, left kidney and liver.  
We performed a genotype-phenotype correlation in which we compared the outcomes in 
the 33 patients in our cohort with confirmed ACTG2 missense substitutions. We divided 
the ACTG2-positive group into arginine substitution and non-arginine substitutions and 
correlated to the previously characterized poor or favorable outcome characterization 
based on transplant, TPN or disease-related mortality. We found that all the poor 
outcomes in the ACTG2-positive group came from individuals with arginine substitutions 
(Figure 5A). Those with an arginine substitution in our cohort had a 57.1% risk of death 
in childhood, TPN dependence and/or transplantation, while we found no individuals 
with non-arginine substitutions suffering these outcomes (Fisher’s Exact test, p=0.0149). 
These results demonstrate a seemingly robust genotype-phenotype correlation in which 
the most severely affected cases invariably have arginine substitutions in ACTG2.  












Next, we examined whether our cohort compared with previously reported cases. We 
collected information from previously published ACTG2 cases and attempted the same 
genotype-phenotype analysis incorporating previously reported cases from the literature 
(Supp. Table S4). Our results were similar to those from the BCM cohort alone. We 
found that the non-arginine substitutions reported were not in association with death, 
transplant or TPN dependence. Interestingly, the arginine substitutions incorporating our 
cohort and the literature had a 63.8% (37/58) chance of poor outcome, an estimate very 
consistent with that from our cohort alone. These differences were statistically significant 
(Fisher’s Exact test p<0.0001). 
We show that the arginine substitutions in general are associated with more severe 
outcomes, but previous studies have suggested specific effects of specific mutations such 
as p.Arg178 (Halim et al., 2016; Ravenscroft et al., 2018). We also compared the 
outcome measure across each of the five recurrent arginine missense mutations (Figure 
5B). Interestingly, we observed that all 17 individuals with missense alleles affecting 
p.Arg178 had a poor outcome compared to 16/26 with a missense mutations affecting 
position p.Arg257 (Fisher’s Exact test, p=0.01) (Figure 5C). For missense substitutions 
affecting residues at positions 40, 63 and 211 there were too few cases (two each) to 
assess. We did observe that cases affecting an arginine residue at position 40 (p.Arg40) 
trended toward a more favorable outcome (6/8). We also examined identification of 
microcolon, and found a striking difference between individuals with p.Arg178 variants 
versus p.Arg257. Out of 20 individuals with p.Arg178, nineteen were found to have 
microcolon, while microcolon was reported in only five out of twenty with p.Arg257 
(Fisher’s Exact test p<0.0001) (Supp. Figure S5). In summary, visceral myopathy 












represents a spectrum of severity and there is a robust genotype-phenotype correlation, 
ACTG2-positive cases are more likely to be severe cases than ACTG2-negative ones, 
arginine missense substitutions are more severe than non-arginine missense alleles. 
Finally, the recurrent arginine alleles impacting p.Arg178 are most severe as a group, 
followed by p.Arg257, then p.Arg40 with insufficient numbers to conclude on other 
arginine substitutions. These data demonstrate that these arginine missense substitutions 
are the primary determinants of the amount and severity of disease in our cohort.  
Discussion 
In this study we utilize a large cohort of 53 families with megacystis, microcolon, 
intestinal hypoperistalsis syndrome (MMIHS) to demonstrate that a set of recurrent 
missense substitutions affecting arginine residues account for the majority of cases. We 
apply a combination of targeted gene sequencing and exome sequencing to show that 
ACTG2 testing has a high diagnostic yield in this clinical population. This is particularly 
true in more severe cases of MMIHS. In addition, we provide evidence for a genotype-
phenotype correlation within ACTG2-positive cases and show that the recurrent missense 
substitutions affecting arginine residues are responsible for cases of MMIHS with poor 
outcomes. Our results have both diagnostic significance for clinical molecular studies of 
patients with MMIHS, as well as prognostic and genetic counseling implications.  
One of the key insights of our study is the central role that ACTG2 mutations and 
particularly arginine missense substitutions play in this spectrum of disease. Previously, 
evidence from some cohorts had also pointed to this predominant role for this locus in 
MMIHS (Ravenscroft et al., 2018), however others have suggested that MMIHS is 












mostly an autosomal recessive disorder and that consanguinity is a major genetic risk 
factor (Nakamura et al., 2019), and indeed a number of recessive loci have been 
described (Gauthier et al., 2015; Halim, Brosens, et al., 2017; Halim, Wilson, et al., 2017; 
Moreno et al., 2018). Our cohort included four families with affected siblings and three 
with consanguinity, but interestingly, one of these cases was ultimately explained by 
dominant inheritance of an ACTG2 variant with incomplete penetrance in the mother. We 
did perform exome sequencing on 17 of the 19 undiagnosed cases in our cohort aimed at 
identifying additional recessive loci, of which one family was found to have a 
homozygous MYLK variant (Halim, Brosens, et al., 2017). However, in our cohort these 
appear to be quite rare, and it was striking to observe more cases in the cohort that affect 
one of the five recurrent arginine substitutions (26/53), and ACTG2 in general (33/53), 
than all those that remain undiagnosed (19/53). 
We also observed a wide range of phenotypic severity in our ACTG2- positive cases, 
ranging from the most severe to older individuals with lifetime abdominal discomfort but 
no firm diagnosis. Our data therefore suggest ACTG2 testing should be considered in a 
much wider range of clinical conditions affecting gastrointestinal or genitourinary 
function. While exome sequencing would seem most advantageous given the ability to 
detect all the known MMIHS loci, ACTG2 targeted testing could be a reasonable 
alternative in some clinical settings, and nearly half of the cases can be diagnosed by 
sequencing five specific CpG dinucleotides within ACTG2.  
These observations also provide a greater context for understanding the recurrent arginine 
missense substitutions in ACTG2. In our larger cohort we saw an obvious impact on 
severity of disease for cases affecting p.Arg178 and p.Arg257 with even greater severity 












in the former group. Of the 18 encoded arginine residues within the ACTG2 gene, 13 are 
at a CpG dinucleotide site. Of these, six are found to be sites of missense substitution 
within gnomAD database. Interestingly, two of these six sites are listed in ClinVar as 
pathogenic variants, p.Arg38 and p.Arg148. One possible interpretation is that these two 
sites are associated with less severe disease. Indeed in our cohort we observed wide 
interfamilial variability for a p.Arg40His variant. With our larger cohort and examining 
other published cases we were able to suggest a severity spectrum for these specific sites 
with p.Arg178 and p.Arg257 accounting for most of the severe cases and p.Arg40 with 
more mixed severity. With the information from gnomAD, an allelic series for severity 
spectrum for these specific alleles could be proposed with 
p.Arg178>p.Arg257>p.Arg40>p.Arg38 and p.Arg148. Whether p.Arg63 and p.Arg211 
also fall into this less severe category will await further studies.  
Regardless of the rates of complications within each group, patients with any severity of 
visceral myopathy face difficult medical challenges and the absence of transplantation or 
lifetime TPN dependence does not reduce the tremendous impact that visceral myopathy 
can have on quality of life, severe medical complications or costly and complex medical 
care. Some individuals in our cohort did undergo transplant, but then had good outcomes 
after their intervention, therefore our data cannot provide an overall prognosis. Instead we 
used TPN dependence, or transplantation as a proxy for gastrointestinal severity. While 
those with a negative ACTG2 sequencing result seem less severe as a group according to 
these measures, a number of severe cases are identified in this cohort. Likewise, while 
ACTG2 positive cases are more likely to have a severe phenotype, individual cases within 
this group can be very mildly impacted. Our results are limited to our own cohort and 












should not be interpreted as predictive for other cases, particularly with negative ACTG2 
results as other genetic factors could impact these cases. Conversely, while nearly all the 
most severe disease occurred in individuals with arginine substitutions, a number of 
individuals with arginine substitutions can have milder phenotypes. Whether additional 
modifier loci could impact severity remains to be determined. In addition, other variants 
in ACTG2 itself could also impact differences in severity. For example, we observed a 
p.Phe110Leu variant affecting an alternate transcript (Uc010fex.1) in two siblings with 
comparatively mild GI disease. We then observed this same variant in another family, in 
which the proband had a de novo p.Arg257 missense allele. Whether this allele could 
secondarily impact severity remains to be determined.  
Our study had some inherent limitations. Our ascertainment, as for any rare disease 
cohort is susceptible to selection bias as we primarily relied on referral to BCM from co-
authors or external researchers or clinicians. With clinical ACTG2 testing now available, 
our study represented families interested in genetic research and seen at academic centers 
which likely selected for more severe cases. We also have recruited individuals over two 
periods of time, from 1999-2001 and then from 2013 to present. Subjects were referred 
for fetal megacystis, microcolon, functional gastrointestinal or functional bladder 
obstruction. In addition, the management of these patients could vary with surgical and 
medical interventions that could complicate the picture of severity. Other groups have 
suggested that very specific clinical designations (such as CIPO with megacystis) need to 
be applied (Matera et al., 2016) and we did not categorize our cases according to these 
clinical designations for analysis purposes. While this might have some advantages, in 
examining our cohort, we observed subjects with the same mutation who can be labeled 












with different clinical designations such as MMIHS, CIPO and hollow visceral myopathy 
by different providers, and in the absence of specific clinical diagnostic criteria, we chose 
to recruit subjects with a range of phenotypes and then analyze according to clinical 
features. While this ascertainment issue is inherent to our study design, it primarily led to 
the inclusion of a number of cases that did not meet strict criteria for MMIHS or CIPO 
and who often ultimately had non-diagnostic molecular studies. This bias would therefore 
lead us to underestimate the impact of ACTG2 in MMIHS/CIPO, which actually 
strengthens our conclusion that ACTG2, and not recessive loci as others have proposed 
(Nakamura et al., 2019), is the primary genetic factor in MMIHS. Indeed, in a highly 
clinically selected cohort it is possible that the rate of ACTG2 positive cases could be 
even higher than 60%. Despite having access to 53 families with this rare condition, our 
numbers still did not allow sufficient power to compare most of the specific mutations 
and additional recruitment will be needed to further study this. Nonetheless, we propose a 
severity spectrum based on our observations in which ACTG2 positive cases are more 
likely to be severe than ACTG2-negative, arginine missense substitutions are more 
common and more severe within the ACTG2 positive group and we propose an arginine 
severity spectrum (p.Arg178>p.Arg63>p.Arg257 >p.Arg40>p.Arg211, p.Arg38 and 
p.Arg148) (Table 2).  
In conclusion, visceral myopathy represents a spectrum of clinical severity due to smooth 
muscle myopathy. We provide an effort to overlay this clinical severity spectrum with a 
molecular classification. In the future, providing classes such as “ACTG2-positive” 
versus “ACTG2-negative” and “p.Arg178” versus “p.Arg40” can help apply molecular 
methods to aid in the classification of a variable set of phenotypes. In addition, testing the 












ACTG2 gene by exome or targeted testing is clearly a promising approach to providing 
better genetic counseling and diagnosis to patients with symptoms ranging from 
newborns with microcolon to adults with longstanding gastrointestinal discomfort.  
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Figures 
Figure 1 – Molecular characterization of the cohort. A – Apparent patterns of 
inheritance in the BCM Visceral Myopathy Cohort. Blue represents sporadic cases in the 
family. Brown represents families with multiple affected members over at least 2 generations 
suggesting a dominant inheritance pattern. Orange represents families with affected siblings 
born to asymptomatic parents suggesting a recessive pattern of inheritance. Red represents 
unknown pattern of inheritance. B – Overall Molecular Diagnosis Rates in the BCM Visceral 
Myopathy Cohort. Blue represents cases with a molecular diagnosis. Orange represents cases 
without a molecular diagnosis. C – Number of cases diagnosed by different molecular strategies 
(exome versus targeted testing). D – Inheritance patterns observed in the cohort. Red represents 
de novo ACTG2 cases. Purple represents ACTG2 cases with unknown pattern of inheritance. 
Blue represents MYLK (autosomal recessive). Orange represents cases lacking a molecular 












diagnosis. E – Variant types in the BCM cohort. Red represents missense variants in ACTG2 
affecting Arginine residues. Purple represents all other ACTG2 variants. Blue represents 
variants in MYLK. Orange represents undiagnosed cases. 
 
  












Figure 2 – Clinical features in the ACTG2 positive versus negative cases. A, B – 
Genitourinary features (megacystis, A, bladder decompression/catheterization, B). Red 
represents cases found to harbor ACTG2 pathogenic variants. Orange represents cases without 
pathogenic variants in ACTG2. C, D – Gastrointestinal features (microcolon, C, abdominal 
surgery in the first weeks of life, D). Brown represents cases with inherited ACTG2 variants or 
variants with unknown inheritance pattern. Red represents cases found to harbor de novo 
ACTG2 pathogenic variants. Orange represents cases without pathogenic variants in ACTG2.  
 












Figure 3 – Burden of disease attributed to ACTG2. A – Proportion of disease complications 
(including megacystis, fetal bladder procedure, bilious emesis, abdominal surgery in the first 
weeks of life, microcolon, abnormal gastrointestinal motility study and need for bladder 
catheterization) that is attributed to all ACTG2 cases, ACTG2 de novo cases and ACTG2 
negative cases. B – Proportion of cases with arginine variants (blue), all other molecularly 
solved cases (light blue) and cases lacking a molecular diagnosis (orange) in the BCM cohort. C 
– Overall outcomes in the cohort. Poor outcome is defined as death in early childhood, 
dependence on total parenteral nutrition or cases undergoing visceral transplant. Favorable 
outcome is defined as lacking these features. Brown represents proportion attributed to ACTG2 
inherited cases or of unknown inheritance. Red represents ACTG2 de novo cases. Orange 
represents ACTG2 negative cases. D – Disease severity in the ACTG2 positive versus ACTG2 
















Figure 4 – ACTG2 variants. A – ACTG2 variants in the BCM cohort. Bars represent 
number of probands with a variant at each position shown (e.g. P39 indicates proline at position 
39 or p.Pro39). The amino acid change is indicated on the graph. B – Arginine residues shown 
on the ACTG2 exon structure. Red labels indicate sites encoded by a “CGX” codon (CpG 
dinucleotides). Blue labels indicate all other Arginine residues. Red stars indicate a recurrently-
mutated site. Positions of the arginine residues are labeled (e.g. R40H/C indicates p.Arg40His 
and p.Arg40Cys). C – Arginine missense variants in public human databases (GnomAD and 
Clinvar). Black filled double circles in gnomAD indicate presence of the allele at Minor allele 
frequency (MAF) >0 in the database. Black dots represent pathogenic or likely pathogenic 
variants in ClinVar. Red boxes represent positions encoded by CpG dinucleotides. Blue boxes 
represent all other Arginine variants. Red stars indicate recurrent pathogenic variants in our 
cohort, all present in ClinVar and absent from GnomAD. Black stars indicate Arginine missense 
alleles that are present in both ClinVar as pathogenic or likely pathogenic variants in ClinVar 
which are also present at MAF>0 in GnomAD.  
 












Figure 5 – Genotype-phenotype correlations for ACTG2 Arginine missense variants. 
Positions of the arginine residues are labeled (e.g. R40 indicates arginine at position 40 or 
p.Arg40). A,B – Outcomes of Arginine versus non-Arginine missense variants in the BCM 
cohort (A) and meta-analysis incorporating cases from the BCM cohort and cases from the 
literature (B). Red bars represent poor outcome defined as death in early childhood, total 
parenteral nutrition dependence and patient undergoing visceral transplant for intestinal 
dysmotility. Blue bars represent cases lacking these features. C – Outcomes of specific Arginine 
missense variants. Red bars represent poor outcome defined as above. Blue bars represent more 
favorable outcomes lacking these features.  
 
  












Table 1 – BCM Visceral Myopathy Cohort overview 
 
All 





Demographics    




16/40 (40) 13/28 (46.4) 3/12 (25) 
24/40 (60) 15/28 (53.6) 9/12 (75) 
Clinical Features    
 GU Features    
 Megacystis 28/36 (77.8) 24/27 (89) 4/9 (44.4) 
 Fetal Bladder Procedure 4/35 (11.4) 3/27 (11.1) 1/8 (12.5) 
 Cath or Vesicostomy 27/34 (79.4) 24/26 (92.3) 3/8 (37.5) 
 GI Features    
 Microcolon 18/34 (52.9) 16/26 (61.5) 2/8 (25) 
 Bilious Emesis 15/32 (46.8) 13/24 (54.2) 2/8 (25) 






















8/36 (22.2) 2/27 (7.4) 6/9 (67) 
 Abdominal Surgery 19/36 (52.7) 15/26 (57.7) 4/10 (40) 
 GI + GU involvement 33/38 (86.8) 28/28 (100) 5/10 (50) 
N indicates number of cases. Total represents cases with complete clinical 
information. Cath – bladder catheterization. GI – gastrointestinal. GU – 
genitourinary.  
Table 2 Genotype Phenotype Correlation for Visceral myopathy 







De novo or 
dominant 
inherited 










De novo or 
dominant 
inherited 
MMIHS or CIPO. Typically Severe neonatal 
presentation usually without microcolon 









De novo or 
dominant 
inherited 
MMIHS or CIPO. Severity range and more 









ACTG2:O De novo or MMIHS or CIPO. Severity range and more Modera












ther Arg dominant 
inherited 








De novo or 
dominant 
inherited 
MMIHS or CIPO. Severity range and more 














Less severe as a group than ACTG2 positive, 









This article is protected by copyright. All rights reserved. 
